Geriatric Cancer PatientsNCT05535140

A Chatbot-Powered G8 Screening Intervention to Facilitate Referrals to a Comprehensive Geriatric Assessment Among Older Adults With Cancer

An observational study of Geriatric Cancer Patients, run by Thomas Jefferson University at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Trial summary

In this prospective quality improvement study, we will develop and evaluate the feasibility and acceptability of an online patient self-reported G8 screening tool which will allow us to efficiently identify G8 positive older cancer patients to be referred to our Senior Adult Oncology Center (SAOC) for a Comprehensive… Read more about this study

Who is it for?: Ages 65 years and older
Conditions the study is for: Geriatric Cancer Patients
What is being tested?: G8 Screening Tool
How many people: 100 participants
Where: 1 siteUnited States
Study dates: 1 Jul 2022to 1 Jan 2024
Phase: Observational
Are there results?: Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 65 years and older
All sexes
No healthy volunteers
Older adult

Study population: Cancer patients who are 65 years of age or older coming to the medical oncology department at Thomas Jefferson University for care.

Who may be able to join

65 years and older
New Patient Visit scheduled for Medical Oncology

Who cannot join

Inability to answer or have caregiver answer questions on screening tool.

Trial locations and contacts

1 site in 1 country.

United States1 site

Sidney Kimmel Cancer Center at Thomas Jefferson University
Philadelphia, Pennsylvania, 19107

Other trials in United States

About this study

Official title: Chatbot Powered G8 Screening Intervention

Read the detailed description

We will test the feasibility and acceptability of the online G8 screening tool developed. 100 older new established cancer patients who had used the MyChart G8 will be recruited to provide their feedback on the usability of the screening tool and any related referral and SAOC appointment experience. Among patients with G8 scores ≤ 14, they will be referred to a CGA. We will examine CGA attendance compliance, predictive value of the online collected G8 score with the final frailty designation determined by the CGA, and perceived barriers among CGA non-adherent patients via a brief follow up inquiry.

Conditions: Geriatric Cancer Patients
Being tested: G8 Screening Tool

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

G8 Screening ToolOther
Determine the feasibility of implementing an online patient self-reported G8 assessment, on new patients >65y/o who are scheduled with the medical oncology department.

Study groups in NCT05535140
Study group	Role	What they receive
Cancer patients who are 65 years of age or older		An online self-reported G8 screening tool. The tool will have content including: 1) the purpose and benefit of the G8, 2) explanations of each question with examples and probes to help with recall, and 3) next steps after the G8 assessment is completed and how the results might impact their cancer treatments. New established older cancer patients will be invited to interact with the tool. Receives: Other: G8 Screening Tool

What is being measured

The primary outcome is the main question the study is designed to answer.

Number of Participants Who Agree to Using the G8 Assessment
To determine the feasibility of implementing an online patient self-reported G8 assessment, on new patients >65y/o who are scheduled with the medical oncology department.
Measured: At Baseline
Number of Participants Who Complete the G8 Assessment
To determine the feasibility of implementing an online patient self-reported G8 assessment, on new patients >65y/o who are scheduled with the medical oncology department.
Measured: At Baseline (approximately 15 minutes)
Number of Participants Who Complete the Referred SAOC Visits if They Complete the G8 Assessment and Are Screened Positive
To determine the feasibility of implementing an online patient self-reported G8 assessment, on new patients >65y/o who are scheduled with the medical oncology department.
Measured: Approximately 2 weeks after G8 completion

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

1 Jul 20221 Jan 2024

First posted10 Sep 2022
Study start1 Jul 2022
Primary completion1 Jan 2023
Study completion1 Jan 2024

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
Other trials for Geriatric Cancer PatientsStudies of the same condition, open and under way.
More trials run by Thomas Jefferson UniversityThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Observational
Observational model: Other
Time perspective: Prospective
Enrolment: 100 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT05535140
Sponsor's protocol ID: 21F.675
Other IDs: 080-27000-S45501, JT 20284, 1R21CA258200-01
Status last verified: Sep 2026
First submitted: 17 Jun 2022
Last updated: 29 Sep 2026
Results posted: Yes, on ClinicalTrials.gov
Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 2
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm
Not yet recruitingPhase 2
Proton Moderately Hypofractionated Radiotherapy in NSCLC Patients Unable to Tolerate Standard Concurrent Chemoradiotherapy
Non-Small Cell Lung Cancer
Recruiting
Remimazolam for Reducing Postoperative Delirium in Elderly Patients Undergoing Laparoscopic Gastrectomy
Gastric Cancer, Postoperative Delirium
Active, not recruitingPhase 2
Chemoradiotherapy Versus Chemotherapy for Elderly and Frail GBM Patients
Glioblastoma Multiforme

All Geriatric Cancer Patients trials

Study at a glance

From the registry record, last updated by the sponsor on 29 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: Chatbot Powered G8 Screening Intervention
ClinicalTrials.gov ID: NCT05535140
Acronym / sponsor ID: 21F.675
Conditions: Geriatric Cancer Patients
Study type: Observational
Recruitment status: Completed
Enrolment: 100 participants (actual)
Lead sponsor: Thomas Jefferson UniversityUniversity, hospital or other
Collaborators: National Cancer Institute (NCI)
Study start: 1 Jul 2022 (actual)
Primary completion: 1 Jan 2023 (actual)
Study completion: 1 Jan 2024 (actual)
First posted: 10 Sep 2022 (actual)
Results: Posted 29 Sep 2026

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Detailed description

Study design

Observational model: Other
Time perspective: Prospective
Number of arms: 1

Arm	Type	Receives
Cancer patients who are 65 years of age or older	–	Other: G8 Screening ToolAn online self-reported G8 screening tool. The tool will have content including: 1) the purpose and benefit of the G8, 2) explanations of each question with examples and probes to help with recall, and 3) next steps after the G8 assessment is completed and how the results might impact their cancer treatments. New established older cancer patients will be invited to interact with the tool.

Who may qualify

Ages: 65 years and older
Sex: All
Healthy volunteers: Not accepted
Age groups: Older adult
Study population: Cancer patients who are 65 years of age or older coming to the medical oncology department at Thomas Jefferson University for care.

Key inclusion criteria (2 listed)

65 years and older
New Patient Visit scheduled for Medical Oncology

Key exclusion criteria (1 listed)

Inability to answer or have caregiver answer questions on screening tool.

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
G8 Screening ToolDetermine the feasibility of implementing an online patient self-reported G8 assessment, on new patients >65y/o who are scheduled with the medical oncology department.	Other	Cancer patients who are 65 years of age or older

Primary outcome

Number of Participants Who Agree to Using the G8 Assessment
Time frame: At Baseline
To determine the feasibility of implementing an online patient self-reported G8 assessment, on new patients >65y/o who are scheduled with the medical oncology department.
Number of Participants Who Complete the G8 Assessment
Time frame: At Baseline (approximately 15 minutes)
To determine the feasibility of implementing an online patient self-reported G8 assessment, on new patients >65y/o who are scheduled with the medical oncology department.
Number of Participants Who Complete the Referred SAOC Visits if They Complete the G8 Assessment and Are Screened Positive
Time frame: Approximately 2 weeks after G8 completion
To determine the feasibility of implementing an online patient self-reported G8 assessment, on new patients >65y/o who are scheduled with the medical oncology department.

Results and safety

Results posted to the registry on 29 Sep 2026, as reported by the sponsor. Figures are copied from the record, not re-analysed. Full results on ClinicalTrials.gov.

Participant flow

Group	Started	Completed
Self-reported G8 Via MyChart	100	100

Primary outcome: Number of Participants Who Agree to Using the G8 Assessment

Time frame: At Baseline. Count of participants. Unit: Participants

Measure	Self-reported G8 Via MyChart n = 100
Value	100

Primary outcome: Number of Participants Who Complete the G8 Assessment

Time frame: At Baseline (approximately 15 minutes). Count of participants. Unit: Participants

Measure	Self-reported G8 Via MyChart n = 100
Value	100

Primary outcome: Number of Participants Who Complete the Referred SAOC Visits if They Complete the G8 Assessment and Are Screened Positive

Time frame: Approximately 2 weeks after G8 completion. Count of participants. Unit: Participants

Measure	Self-reported G8 Via MyChart n = 5
Value	5

Adverse events

Time frame: Approximately 2 weeks. Other adverse events reported at 0% frequency or more

Group	Serious adverse events	Other adverse events	Deaths
Cancer Patients Who Are 65 Years of Age or Older	0 of 100 (0%)	0 of 100 (0%)	0 of 100

Loading the posted results from ClinicalTrials.gov…

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 29 Sep 2026.
Posted resultsParticipant flow, baseline, all outcome measures and adverse events.

Related trials for Geriatric Cancer Patients

Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 2
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm
Not yet recruitingPhase 2
Proton Moderately Hypofractionated Radiotherapy in NSCLC Patients Unable to Tolerate Standard Concurrent Chemoradiotherapy
Non-Small Cell Lung Cancer
Recruiting
Remimazolam for Reducing Postoperative Delirium in Elderly Patients Undergoing Laparoscopic Gastrectomy
Gastric Cancer, Postoperative Delirium
Active, not recruitingPhase 2
Chemoradiotherapy Versus Chemotherapy for Elderly and Frail GBM Patients
Glioblastoma Multiforme

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

Kuang-Yi Wen, PhD principal investigator

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

1 site in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

An observational study of Geriatric Cancer Patients, run by Thomas Jefferson University at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 29 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 29 Sep 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Participants Who Agree to Using the G8 Assessment (time frame: At Baseline). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05535140.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Sep 2026.